DNA repair disease
MONDO:0021190A disease that has its basis in the disruption of DNA repair.
Also known as: DNA repair disorder, deficiency of DNA repair, disorder of DNA repair, DNA Repairs, deficient, DNA repair deficiency, DNA repair deficiency disorders, DNA repair, deficient, DNA repair-deficiencies
105 clinical trials for this condition and its sub-types, 13 tagged with DNA repair disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of DNA repair disease
-
Fanconi anemia 29 trials · 42 incl. sub-types
22 sub-types
- Fanconi anemia complementation group D1 6 trials
- Fanconi anemia complementation group A 4 trials
- Fanconi anemia complementation group E 4 trials
- Fanconi anemia complementation group N 2 trials
- Fanconi anemia, complementation group S 2 trials
- Fanconi anemia complementation group B 0 trials
- Fanconi anemia complementation group C 0 trials
- Fanconi anemia complementation group D2 0 trials
- Fanconi anemia complementation group F 0 trials
- Fanconi anemia complementation group G 0 trials
- Fanconi anemia complementation group I 0 trials
- Fanconi anemia complementation group J 0 trials
- Fanconi anemia complementation group L 0 trials
- Fanconi anemia complementation group O 0 trials
- Fanconi anemia complementation group P 0 trials
- Fanconi anemia complementation group Q 0 trials
- Fanconi anemia complementation group R 0 trials
- Fanconi anemia complementation group T 0 trials
- Fanconi anemia complementation group U 0 trials
- Fanconi anemia complementation group V 0 trials
- Fanconi anemia, complementation group W 0 trials
- Fanconi anemia, complementation group 10 0 trials
-
Mismatch repair cancer syndrome 5 trials · 36 incl. sub-types
4 sub-types
- Mismatch repair cancer syndrome 1 34 trials
- Mismatch repair cancer syndrome 2 0 trials
- Mismatch repair cancer syndrome 3 0 trials
- Mismatch repair cancer syndrome 4 0 trials
-
Cockayne syndrome 6 trials
4 sub-types
- Cockayne spectrum with or without cerebrooculofacioskeletal syndrome 0 trials
- Cockayne syndrome type 1 0 trials
- Cockayne syndrome type 2 0 trials
- Cockayne syndrome type 3 0 trials
-
Xeroderma pigmentosum 4 trials · 6 incl. sub-types
10 sub-types
- Xeroderma pigmentosum group F 1 trial
- Xeroderma pigmentosum variant type 1 trial
- Xeroderma pigmentosum group A 0 trials
- Xeroderma pigmentosum group B 0 trials
- Xeroderma pigmentosum group C 0 trials
- Xeroderma pigmentosum group D 0 trials
- Xeroderma pigmentosum group E 0 trials
- Xeroderma pigmentosum group G 0 trials
- Xeroderma pigmentosum, autosomal dominant, mild 0 trials
- Xeroderma pigmentosum, complementation group J 0 trials
-
Karyomegalic interstitial nephritis 2 trials
-
Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 0 trials · 2 incl. sub-types
-
COFS syndrome 1 trial
5 sub-types
- Cerebrooculofacioskeletal syndrome 1 0 trials
- Cerebrooculofacioskeletal syndrome 2 0 trials
- Cerebrooculofacioskeletal syndrome 3 0 trials
- Cerebrooculofacioskeletal syndrome 4 0 trials
- Xeroderma pigmentosum group G 0 trials
-
Nijmegen breakage syndrome 1 trial
-
UV-sensitive syndrome 0 trials
3 sub-types
- UV-sensitive syndrome 1 0 trials
- UV-sensitive syndrome 2 0 trials
- UV-sensitive syndrome 3 0 trials
-
Photosensitive trichothiodystrophy 0 trials
3 sub-types
- Trichothiodystrophy 1, photosensitive 0 trials
- Trichothiodystrophy 2, photosensitive 0 trials
- Trichothiodystrophy 3, photosensitive 0 trials
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called AZD4956, alone or with other cancer drugs, in people with advanced or spreading solid tumors that have a specific DNA repair defect (HRR deficiency). The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. …
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug combo targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new oral drug called MOMA-313, alone or with another drug (olaparib), in people with advanced solid tumors that have certain DNA repair flaws. The main goals are to check safety and find the right dose. About 220 adults with cancers like prostate, p…
Phase 1 • Sponsor: MOMA Therapeutics • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Scientists track rare DNA repair diseases to learn how they progress
Knowledge-focused Recruiting nowThis study is for people with rare DNA repair disorders like Cockayne syndrome, xeroderma pigmentosum, or trichothiodystrophy. Researchers will watch how symptoms like movement and balance change over time. No treatments are given—the goal is to better understand these conditions…
Sponsor: University of Minnesota • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC